Flemming Ørnskov
SwitzerlandbusinessmanMale7.0Global Dominance: 0.00%Flemming Ørnskov is the CEO of Galderma, a global dermatology company that has gained attention for its innovative biopharmaceuticals, including the recently approved therapeutic drug Nemluvio. Ørnskov has a strong background in the pharmaceutical industry, having previously held leadership roles at Shire, and is focused on successfully bringing new treatments to market while navigating the complexities of a rapidly evolving healthcare landscape.
Power618
Reach7,645
Country presence
Recent news mentions
Flemming Ørnskov, the CEO, has previously held leadership positions at major pharmaceutical companies.
Die Aktien von Galderma sind kurzfristig ausgereiztNeue Zürcher Zeitung·Switzerland· 2026-08-09
Switzerland· 2026-08-09
Flemming Ørnskov is the CEO of Galderma and has high expectations for the new drug Nemluvio.
Helvetia-Baloise-Fusion: Grätscht Zurich noch dazwischen?Neue Zürcher Zeitung·Switzerland· 2025-04-25
Switzerland· 2025-04-25
